These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 25780983)

  • 1. Dermatitis medicamentosa: severe rebound erythema secondary to topical brimonidine in rosacea.
    Werner K; Kobayashi TT
    Dermatol Online J; 2015 Jan; 21(3):. PubMed ID: 25780983
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Erythema in Skin Adjacent to Area of Long-term Brimonidine Treatment for Rosacea: A Novel Adverse Reaction.
    Gillihan R; Nguyen T; Fischer R; Rajpara A; Aires D
    JAMA Dermatol; 2015 Oct; 151(10):1136-7. PubMed ID: 26083825
    [No Abstract]   [Full Text] [Related]  

  • 3. Allergic contact dermatitis caused by Mirvaso®, brimonidine tartrate gel 0.33%, a new topical treatment for rosaceal erythema.
    Cookson H; McFadden J; White J; White IR
    Contact Dermatitis; 2015 Dec; 73(6):366-7. PubMed ID: 26768997
    [No Abstract]   [Full Text] [Related]  

  • 4. Paradoxical Erythema Reaction of Long-term Topical Brimonidine Gel for the Treatment of Facial Erythema of Rosacea.
    Lowe E; Lim S
    J Drugs Dermatol; 2016 Jun; 15(6):763-5. PubMed ID: 27272086
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of once-daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of two randomized, double-blind, and vehicle-controlled pivotal studies.
    Fowler J; Jackson M; Moore A; Jarratt M; Jones T; Meadows K; Steinhoff M; Rudisill D; Leoni M
    J Drugs Dermatol; 2013 Jun; 12(6):650-6. PubMed ID: 23839181
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sensitization to and allergic contact dermatitis caused by Mirvaso(®) (brimonidine tartrate) for treatment of rosacea - 2 cases.
    Bangsgaard N; Fischer LA; Zachariae C
    Contact Dermatitis; 2016 Jun; 74(6):378-9. PubMed ID: 27133629
    [No Abstract]   [Full Text] [Related]  

  • 7. Optical coherence tomography imaging of erythematotelangiectatic rosacea during treatment with brimonidine topical gel 0.33%: a potential method for treatment outcome assessment.
    Urban J; Siripunvarapon AH; Meekings A; Kalowitz A; Markowitz O
    J Drugs Dermatol; 2014 Jul; 13(7):821-6. PubMed ID: 25007365
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A case report of combination treatment with potassium-titanyl phosphate laser and brimonidine topical gel in erythematotelangiectatic rosacea.
    Hofmann MA; Kokolakis G
    J Cosmet Laser Ther; 2017 Aug; 19(4):222-224. PubMed ID: 28139145
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimizing the use of topical brimonidine in rosacea management: panel recommendations.
    Tanghetti EA; Jackson JM; Belasco KT; Friedrichs A; Hougier F; Johnson SM; Kerdel FA; Palceski D; Hong HC; Hinek A; Cadena MJ
    J Drugs Dermatol; 2015 Jan; 14(1):33-40. PubMed ID: 25607906
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of Rosacea With Concomitant Use of Topical Ivermectin 1% Cream and Brimonidine 0.33% Gel: A Randomized, Vehicle-controlled Study.
    Gold LS; Papp K; Lynde C; Lain E; Gooderham M; Johnson S; Kerrouche N
    J Drugs Dermatol; 2017 Sep; 16(9):909-916. PubMed ID: 28915286
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Once-daily topical brimonidine tartrate gel 0·5% is a novel treatment for moderate to severe facial erythema of rosacea: results of two multicentre, randomized and vehicle-controlled studies.
    Fowler J; Jarratt M; Moore A; Meadows K; Pollack A; Steinhoff M; Liu Y; Leoni M;
    Br J Dermatol; 2012 Mar; 166(3):633-41. PubMed ID: 22050040
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rosacea or photodamaged skin? Use of brimonidine gel in differentiating erythema in the two conditions.
    Oon HH; Lim ZV
    Australas J Dermatol; 2017 Feb; 58(1):63-64. PubMed ID: 26763464
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Brimonidine gel 0.33% rapidly improves patient-reported outcomes by controlling facial erythema of rosacea: a randomized, double-blind, vehicle-controlled study.
    Layton AM; Schaller M; Homey B; Hofmann MA; Bewley AP; Lehmann P; Nohlgård C; Sarwer DB; Kerrouche N; Ma YM
    J Eur Acad Dermatol Venereol; 2015 Dec; 29(12):2405-10. PubMed ID: 26416154
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of topical brimonidine in dermatology: A review article.
    Saki N; Amani M; Nezhad NZ; Shahpar A; Shafiei M; Hosseini SA; Ahramiyanpour N
    Dermatol Ther; 2022 Nov; 35(11):e15819. PubMed ID: 36097378
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Brimonidine (Mirvaso), dermal use].
    Van Genechten D
    J Pharm Belg; 2015 Jun; (2):45-6. PubMed ID: 26466509
    [No Abstract]   [Full Text] [Related]  

  • 16. Erythematotelangiectatic rosacea: The combination of 0.5% brimonidine tartrate gel and broadband pulse light therapy to reverse its effects.
    Rusina T; Snarskaya E
    J Cosmet Dermatol; 2021 Jul; 20(7):2116-2118. PubMed ID: 33179326
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Case Report: Allergic Contact Dermatitis to Topical Brimonidine Demonstrated With Patch Testing: Insights on Evaluation of Brimonidine Sensitization.
    Ringuet J; Houle MC
    J Cutan Med Surg; 2018; 22(6):636-638. PubMed ID: 30016883
    [No Abstract]   [Full Text] [Related]  

  • 18. Primum non nocere; the importance of evaluating the effect of treatment and considering side effects.
    Sukakul T; Dahlin J; Svedman C
    Contact Dermatitis; 2021 Feb; 84(2):121-122. PubMed ID: 32713000
    [No Abstract]   [Full Text] [Related]  

  • 19. Facial Erythema of Rosacea - Aetiology, Different Pathophysiologies and Treatment Options.
    Steinhoff M; Schmelz M; Schauber J
    Acta Derm Venereol; 2016 Jun; 96(5):579-86. PubMed ID: 26714888
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improvement in facial erythema within 30 minutes of initial application of brimonidine tartrate in patients with rosacea.
    Jackson JM; Fowler J; Moore A; Jarratt M; Jones T; Meadows K; Steinhoff M; Rudisill D; Leoni M;
    J Drugs Dermatol; 2014 Jun; 13(6):699-704. PubMed ID: 24918560
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.